Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(5S,6R,15R)-5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID, also known as Lipoxin A4, 15-epi, is a bioactive molecule that belongs to the eicosanoid family. It is a lipid mediator derived from arachidonic acid through the action of lipoxygenase enzymes. (5S,6R,15R)-5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID exhibits unique stereochemistry and possesses potent anti-inflammatory and pro-resolving properties. Its structure and bioactivity make it a promising candidate for therapeutic applications in various inflammatory and immune-related disorders.

171030-11-8

Post Buying Request

171030-11-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (5S,6R,15R)-5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID

    Cas No: 171030-11-8

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier

171030-11-8 Usage

Uses

Used in Pharmaceutical Industry:
(5S,6R,15R)-5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID is used as an anti-inflammatory agent for its ability to block the release of pro-inflammatory cytokines, such as IL-8. This makes it a potential therapeutic agent for treating inflammatory conditions, such as arthritis, asthma, and inflammatory bowel disease.
Used in Immunomodulation:
(5S,6R,15R)-5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID is used as an immunomodulatory agent for its ability to promote the resolution of inflammation and enhance tissue repair. Its pro-resolving properties make it a promising candidate for the treatment of chronic inflammatory and autoimmune diseases, such as lupus, multiple sclerosis, and rheumatoid arthritis.
Used in Drug Development:
(5S,6R,15R)-5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID is used as a lead compound in drug development for its unique stereochemistry and bioactivity. Researchers are exploring its potential as a template for the design and synthesis of novel analogs with improved pharmacological properties, such as enhanced stability, bioavailability, and target selectivity.
Used in Cosmetic Industry:
(5S,6R,15R)-5,6,15-TRIHYDROXY-7,9,13-TRANS-11-CIS-EICOSATETRAENOIC ACID is used as an anti-aging and skin health ingredient in cosmetic formulations. Its anti-inflammatory and pro-resolving properties can help reduce skin inflammation, promote skin repair, and improve skin appearance by reducing wrinkles and fine lines.

Check Digit Verification of cas no

The CAS Registry Mumber 171030-11-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,1,0,3 and 0 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 171030-11:
(8*1)+(7*7)+(6*1)+(5*0)+(4*3)+(3*0)+(2*1)+(1*1)=78
78 % 10 = 8
So 171030-11-8 is a valid CAS Registry Number.

171030-11-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 5(S),6(R),15(R)-Lipoxin A4

1.2 Other means of identification

Product number -
Other names LXA4-15-EPI

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:171030-11-8 SDS

171030-11-8Downstream Products

171030-11-8Relevant articles and documents

Total synthesis of aspirin-triggered 15-epi-lipoxin A4

Rodríguez, Ana R,Spur, Bernd W

, p. 6057 - 6060 (2001)

The total synthesis of aspirin-triggered 15-epi-LXA4 has been achieved using a chiral pool strategy for the C1-C12 fragment starting from 2-deoxy-D-ribose. Sharpless catalytic AE generated the C15 chiral center with >98% ee. The stereospecific (Z)-reduction of the conjugated trienyne to the tetraene was achieved with Zn(Cu/Ag) in aq. CH3OH at rt.

5 S,15 S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1

Green, Abigail R.,Freedman, Cody,Tena, Jennyfer,Tourdot, Benjamin E.,Liu, Benjamin,Holinstat, Michael,Holman, Theodore R.

, p. 6726 - 6734 (2018/11/27)

The reaction of 5S,15S-dihydroperoxyeicosatetraenoic acid (5,15-diHpETE) with human 5-lipoxygenase (LOX), human platelet 12-LOX, and human reticulocyte 15-LOX-1 was investigated to determine the reactivity and relative rates of producing lipoxins (LXs). 5-LOX does not react with 5,15-diHpETE, although it can produce LXA4 when 15-HpETE is the substrate. In contrast, both 12-LOX and 15-LOX-1 react with 5,15-diHpETE, forming specifically LXB4. For 12-LOX and 5,15-diHpETE, the kinetic parameters are kcat = 0.17 s-1 and kcat/KM = 0.011 μM-1 s-1 [106- and 1600-fold lower than those for 12-LOX oxygenation of arachidonic acid (AA), respectively]. On the other hand, for 15-LOX-1 the equivalent parameters are kcat = 4.6 s-1 and kcat/KM = 0.21 μM-1 s-1 (3-fold higher and similar to those for 12-HpETE formation by 15-LOX-1 from AA, respectively). This contrasts with the complete lack of reaction of 15-LOX-2 with 5,15-diHpETE [Green, A. R., et al. (2016) Biochemistry 55, 2832-2840]. Our data indicate that 12-LOX is markedly inferior to 15-LOX-1 in catalyzing the production of LXB4 from 5,15-diHpETE. Platelet aggregation was inhibited by the addition of 5,15-diHpETE, with an IC50 of 1.3 μM; however, LXB4 did not significantly inhibit collagen-mediated platelet activation up to 10 μM. In summary, LXB4 is the primary product of 12-LOX and 15-LOX-1 catalysis, if 5,15-diHpETE is the substrate, with 15-LOX-1 being 20-fold more efficient than 12-LOX. LXA4 is the primary product with 5-LOX but only if 15-HpETE is the substrate. Approximately equal proportions of LXA4 and LXB4 are produced by 12-LOX but only if LTA4 is the substrate, as described previously [Sheppard, K. A., et al. (1992) Biochim. Biophys. Acta 1133, 223-234].

COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION

-

Paragraph 321, (2018/01/17)

The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

Stereoselective total synthesis of 5(S), 6(R), 15(S)-trihydroxy-7(E), 9(E), 11(Z), 13(E)-eicosatetraenoic acid (Lipoxin A)

Yadav,Barma,Dutta, Dinah

, p. 143 - 146 (2007/10/03)

A stereoselective synthesis of the title compound from D-xylose using zinc mediated deoxygenation of 4-hydroxy-2-butenoic acid moiety and base induced double elimination of 4,5-epoxy allyl chloride as key steps is described.

SYNTHESIS OF 5S-HYDROXY-14,15 LTA4 A BIOGENIC PRECURSOR TO THE LIPOXINS

Leblanc, Yves,Fitzsimmons, Brian J.,Rokach, Joshua

, p. 3449 - 3452 (2007/10/02)

A synthesis of 5S-hydroxy-14,15-LTA4 10 an intermediate in the biosynthesis of the lipoxins is described.

Stereocontrolled Total Synthesis of Lipoxins A

Nicolau, K. C.,Veale, C. A.,Webber, S. E.,Katerinopoulos, H.

, p. 7515 - 7518 (2007/10/02)

A stereocontrolled total synthesis of lipoxin A and a number of its isomers is reported.The strategy involves Sharpless asymmetric epoxidation and pinylborane asymmetric reduction to build the hydroxy-bearing stereocenters and a Wittig-type as well as a P

SIMPLE SYNTHESIS AND ASSIGNMENT OF STEREOCHEMISTRY OF LIPOXIN A

Corey, E. J.,Su, Wei-gou

, p. 281 - 284 (2007/10/02)

A synthesis of lipoxin A, a recently descovered biologically active eicosanoid, and the assignment of stereoformula 1 is reported herein.

Enantiospecific and Stereospecific Synthesis of Lipoxin A. Stereochemical Assignment of the Natural Lipoxin A and Its Possible Biosynthesis

Adams, Julian,Fitzsimmons, Brian J.,Girard, Yves,Leblanc, Yves,Evans, Jillian F.,Rokach, Joshua

, p. 464 - 469 (2007/10/02)

Both chemical and enzymatic steps were employed to convert leukotriene A4 and its unnatural epoxide isomers into four diastereomeric 5(S),6(S),15(S)-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acids, possible structures for lipoxin A.These compounds were correlated with trihydroxy tetraene eicosatetraenoic acids derived from tetraene epoxide 3, and the relative stereochemistries of the 5 and 6 positions were assigned.These assignments were confirmed by total synthesis of two diastereomers of lipoxin A.One of these isomers, 5(S),6(S),15(S)-trihydroxy-7-9,13-trans-11-cis-eicosatetraenoic acid (1b), corresponded to lipoxin A derived from natural sources.The structure and possible biosyntheses of lipoxin A are proposed.

SYNTHESIS OF LIPOXINS: TOTAL SYNTHESIS OF CONJUGATED TRIHYDROXY EICOSATETRAENOIC ACIDS

Adams, Julian,Fitzsimmons, Brian. J.,Rokach, Joshua

, p. 4713 - 4716 (2007/10/02)

The first synthesis of a conjugated trihydroxy eicosatetraenoic acid, a possible structure for Lipoxin A is described.A biomimetic approach was utilized.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 171030-11-8